Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.For the treatment of ADHD in children and adolescents ages 6 to 17
Subscribe to our email newsletter
Shire has launched Intuniv (guanfacine) extended release tablets in pharmacies across the US for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.
Intuniv, a once-daily formulation of guanfacine, is a nonscheduled alpha-2A receptor agonist approved for the treatment of ADHD. In clinical trials, Intuniv provided significant efficacy across the spectrum of ADHD symptoms that can be disruptive, such as being easily distracted, interrupting others, running around excessively, arguing with adults, and losing temper.
Reportedly, the FDA has approved Intunivon on September 2, 2009. Once-daily Intunivis now available in US pharmacies in four dosage strengths (1mg, 2mg, 3mg, and 4mg).
Rakesh Jain, director of psychopharmacology research at R/D Clinical Research, in Texas, said: “Intuniv has been shown to improve a range of ADHD symptoms and provides prescribers and patients with another treatment option for this complex disorder. In clinical studies, Intuniv was shown to provide significant ADHD symptom improvement across a full day, as reported by parents at approximately 6 PM, 8 PM, and 6 AM the next morning.
“These findings suggest that Intunivmay be an important treatment option for children and adolescents with ADHD who are faced with the complexities of the disorder, both at school and at home. Because of this, many clinicians such as myself, have been highly anticipating its availability.”
Michael Yasick, senior vice president of the ADHD business unit at Shire, said: “Intunivis the newest ADHD treatment to receive FDA approval and the latest addition to the Shire ADHD portfolio. The availability of Intunivnow allows physicians to prescribe the first and only nonscheduled alpha-2A receptor agonist indicated for the treatment of ADHD to help their patients manage a range of ADHD symptoms Shire is proud to provide physicians and the ADHD community with a novel treatment choice, which expands the range of available treatment options, allowing physicians to optimise the management of ADHD.”